Cargando…
Honokiol Ameliorates Post-Myocardial Infarction Heart Failure Through Ucp3-Mediated Reactive Oxygen Species Inhibition
Post-myocardial infarction heart failure (post-MI HF) is one of the leading global causes of death, and current prevention and treatment methods still cannot avoid the increasing incidence. Honokiol (HK) has previously been reported to improve myocardial ischemia/reperfusion injury and reverse myoca...
Autores principales: | Liu, Jianyu, Tang, Minghai, Li, Tao, Su, Zhengying, Zhu, Zejiang, Dou, Caixia, Liu, Yan, Pei, Heying, Yang, Jianhong, Ye, Haoyu, Chen, Lijuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899544/ https://www.ncbi.nlm.nih.gov/pubmed/35264952 http://dx.doi.org/10.3389/fphar.2022.811682 |
Ejemplares similares
-
Corrigendum: Honokiol ameliorates post-myocardial infarction heart failure through Ucp3-mediated reactive oxygen species inhibition
por: Liu, Jianyu, et al.
Publicado: (2022) -
Non-toxic dose of liposomal honokiol suppresses metastasis of hepatocellular carcinoma through destabilizing EGFR and inhibiting the downstream pathways
por: Yang, Jianhong, et al.
Publicado: (2016) -
Honokiol attenuate the arsenic trioxide‐induced cardiotoxicity by reducing the myocardial apoptosis
por: Huang, An‐Liang, et al.
Publicado: (2022) -
Correction: Non-toxic dose of liposomal honokiol suppresses metastasis of hepatocellular carcinoma through destabilizing EGFR and inhibiting the downstream pathways
por: Yang, Jianhong, et al.
Publicado: (2020) -
Therapeutic efficacy of an injectable formulation of purinostat mesylate in SU-DHL-6 tumour model
por: Zhu, Zejiang, et al.
Publicado: (2022)